HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This is not an authorized publication; it is the continuous build for version 0.1.0. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

PlanDefinition: GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel

Official URL: https://fhir.nzf.org.nz/fhir/PlanDefinition/60071000210106 Version: 0.1.0
Active as of 2022-10-28 Computable Name: GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel
Other Identifiers: id: SNOMED CT International Edition#60071000210106

Usage:Clinical Focus: Gynaecological, Clinical Focus: Endometrial

Copyright/Legal: All rights reserved.

A drug treatment regimen for Gynaecological Endometrial Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel

GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel

Treatment Overview

This regimen consists of two parts: cISplatin chemoradiation followed by cARBOplatin and PACLItaxel.

Do not confuse with the chemotherapy-only regimen: GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only].

​ Part 1: cISplatin chemoradiation

Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy.

​ Part 2: cARBOplatin and PACLItaxel

Commence within 3 weeks after completion of radiation therapy.

Supportive Care Factors

Factor Value
Emetogenicity: High
Growth factor support: Variable
Hydration: Variable
Hypersensitivity / Infusion related reaction risk: Variable

References

de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189

de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040

de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626

Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641., PMID: 25089112

Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021).

Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020).

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.